NEW YORK (GenomeWeb) – CRISPR-based therapy developer Editas Medicine is looking to raise up to $122 million in a planned initial public offering, according to an amended prospectus filed today with the US Securities and Exchange Commission.

According to the amended Form S-1, Editas has registered to sell 5.9 million shares with a proposed price per share between $16 and $18, for a maximum offering price just over $122 million. The firm will also offer 885,000 shares of common stock to the underwriters to cover over-allotments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.